Skip to main content

Table 1 Baseline covariates in two trials

From: Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials

 

All

(n = 112)

BGB-3111-AU-003

(n = 33)

BGB-3111-206

(n = 79)

Age

 Mean (SD)

61.55 (9.97)

69.12 (9.93)

58.39 (8.16)

 Median

62

70

60

Sex, male

86 (77%)

25 (76%)

61 (77%)

BMI, mean (SD)

24.94 (4.18)

27.88 (4.82)

23.72 (3.19)

ECOG PS, > 1

6 (5%)

3 (9%)

3 (4%)

Disease stage

 I

3 (3%)

2 (6%)

1 (1%)

 II

7 (6%)

0

7 (9%)

 III

14 (13%)

1 (3%)

13 (16%)

 IV

88 (79%)

30 (91%)

58 (73%)

Number of prior lines of therapy, median

2

1

2

Blastoid variant

14 (13%)

2 (6%)

12 (15%)

MIPI

 High risk

24 (21%)

15 (45%)

9 (11%)

 Intermediate risk

33 (29%)

10 (30%)

23 (29%)

 Low risk

55 (49%)

8 (24%)

47 (59%)

Bulky

9 (8%)

3 (9%)

6 (8%)

Extra-nodal

67 (60%)

9 (27%)

58 (73%)

Bone marrow involvement

58 (52%)

21 (64%)

37 (47%)

  1. BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, Bulky longest transverse diameter of a lesion > 10 cm, SD standard deviation